Marvel Biosciences Announces Grant of Deferred Share Units

Core Viewpoint - Marvel Biosciences Corp. has awarded 142,987 deferred share units (DSUs) to two directors as a form of compensation instead of cash payment, with the DSUs set to vest on July 31, 2026 [1][2]. Group 1: Company Overview - Marvel Biosciences Corp. is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company [3]. - The company is developing MB-204, a novel fluorinated derivative of the anti-Parkinson's drug Istradefylline, which is the only clinically approved adenosine A2a antagonist [3]. - There is growing scientific evidence suggesting that drugs blocking the adenosine A2a receptor, like MB-204, may be effective in treating various neurological diseases, including autism, depression, and Alzheimer's Disease [3]. - The company is also exploring the potential of MB-204 in addressing neurodevelopmental disorders such as Rett Syndrome and Fragile X Syndrome to broaden its therapeutic applications [3]. Group 2: Financial Details - The deemed value of the awarded DSUs is calculated at $0.16 per share based on the volume-weighted average price (VWAP) of the company's common shares on the TSX Venture Exchange as of July 31, 2025 [2]. - Vested DSUs will be settled upon the directors' separation from the company and will expire 365 days after such separation [2].